411 related articles for article (PubMed ID: 23742290)
1. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
[TBL] [Abstract][Full Text] [Related]
2. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
3. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
4. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
6. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
[TBL] [Abstract][Full Text] [Related]
7. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
[TBL] [Abstract][Full Text] [Related]
8. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
9. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
Súss SKA; Mesa CO; Carvalho GA; Miasaki FY; Chaves CP; Fuser DC; Corbo R; Momesso D; Bulzico DA; Graf H; Vaisman F
Arch Endocrinol Metab; 2018; 62(2):149-156. PubMed ID: 29641738
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
12. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
[TBL] [Abstract][Full Text] [Related]
13. Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma?
Chéreau N; Buffet C; Trésallet C; Tissier F; Golmard JL; Leenhardt L; Menegaux F
Ann Surg Oncol; 2014 May; 21(5):1659-64. PubMed ID: 24394985
[TBL] [Abstract][Full Text] [Related]
14. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation.
Sawka AM; Rilkoff H; Tsang RW; Brierley JD; Rotstein L; Ezzat S; Asa SL; Segal P; Kelly C; Zahedi A; Gafni A; Goldstein DP
Thyroid; 2013 Feb; 23(2):246-7. PubMed ID: 23009127
[No Abstract] [Full Text] [Related]
15. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
16. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery.
Conzo G; Mauriello C; Docimo G; Gambardella C; Thomas G; Cavallo F; Tartaglia E; Napolitano S; Varriale R; Rossetti G; Fei L; Santini L
Int J Surg; 2014; 12 Suppl 1():S194-7. PubMed ID: 24862675
[TBL] [Abstract][Full Text] [Related]
18. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
19. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
